Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 1 of the 22 sources its claims cite were checked for support.

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Open access
Ahn, Myung-Ju, Tanaka, Kentaro, Paz-Ares, Luis, Cornelissen, Robin, Girard, Nicolas, Pons-Tostivint, Elvire, Vicente Baz, David, Sugawara, Shunichi, Cobo, Manuel, Pérol, Maurice, Mascaux, Céline, Poddubskaya, Elena, Kitazono, Satoru, Hayashi, Hidetoshi, Hong, Min Hee, Felip, Enriqueta, Hall, Richard, Juan-Vidal, Oscar, Brungs, Daniel, Lu, Shun, Garassino, Marina, Chargualaf, Michael, Zhang, Yong, Howarth, Paul, Uema, Deise, Lisberg, Aaron, Sands, Jacob, for the TROPION-Lung01 Trial Investigators, Martinengo, Gaston Lucas, Puig, Juan, Brungs, Daniel, Gao, Bo, Nagria, Adnan, Karapetis, Chris, Parakh, Sagun, Park, John, Catala, Gaetan, Forget, Frederic, Ocak, Sebahat, Basappa, Naveen, Liu, Geoffrey, Menjak, Ines, Shieh, Benjamin, Lu, Shun, Luo, Feng, Sun, Hongmei, Wang, Jialei, Yao, Yu, Zemanova, Milada, Bennouna, Jaafar, Girard, Nicolas, Greillier, Laurent, Lamour, Corinne, Lena, Herve, Mascaux, Céline, Mazieres, Julien, Moro-Sibilot, Denis, Pérol, Maurice, Pons-Tostivint, Elvire, Westeel, Virginie, Atmaca, Akin, Greil, Christine, Reinmuth, Niels, Schumann, Christian, Wehler, Thomas, Wolf, Juergen, Ho, James, Bocskei, Csaba, Cappuzzo, Federico, de Marinis, Filippo, Proto, Claudia, Mencoboni, Manlio, Novello, Silvia, Salvagni, Stefania, Parra, Hector Soto, Daga, Haruko, Goto, Yasushi, Hayashi, Hidetoshi, Kitazono, Satoru, Yoh, Kiyotaka, Ko, Ryo, Kondo, Masashi, Kozuki, Toshiyuki, Kurata, Takayasu, Mizutani, Hideaki, Ohashi, Kadoaki, Oizumi, Satoshi, Okamoto, Isamu, Sakaguchi, Satoshi, Ozasa, Hiroaki, Sugawara, Shunichi, Tambo, Yuichi, Tamiya, Motohiro, Tanaka, Hiroshi, Okamoto, Isamu, Lopez-Lopez, Froylan, Ramirez Godinez, Francisco Javier, Rodriguez Cid, Jeronimo Rafael, Cornelissen, Robin, Gans, Steven, Stigt, Jos, Kowalski, Dariusz, Lowczak, Anna, Milanowski, Janusz, Mróz, Robert, Ramlau, Rodryg, Acosta-Rivera, Mirelis, Ahn, Myung-Ju, Chae, Yee Soo, Hong, Min Hee, Kang, Jin-Hyoung, Kim, Sang-We, Kim, Jin-Soo, Kim, Se Hyun, Lee, Ki Hyeong, Lee, Yun Gyoo, Shim, Byoung Yong, Ledin, Evgeniy, Poddubskaya, Elena, Daniel Chan, Boon Yeow, Jain, Amit, Tan, Chee Seng, Areses, Maria Carmen, Cobo, Manuel, Domine, Manuel, Felip, Enriqueta, Pradera, José Fuentes, Isla, Dolores, Vidal, Oscar Juan, Majem, Margarita, Paz-Ares, Luis, Provencio, Mariano, Reguart, Noemi, Baz, David Vicente, Cerciello, Ferdinando, Früh, Martin, Chang, Wen-Cheng, Chang, Gee-Chen, Huang, Wen-Tsung, Ling, Chien-Chung, Wei, Yu-Feng, Yang, Tsung-Ying, Ahmad, Tanya, Gomes, Fabio, Mansy, Talal, Bruno, Debora, Castine, Michael, Fang, Bruno, Garassino, Marina, Hall, Richard, Halmos, Balazs, Jahangir, Khawaja, Johnson, Melissa, Johnson, Tirrell, Kalmadi, Sujith, Lawler, William, Lisberg, Aaron, Sadiq, Ahad, Sands, Jacob, Solomon, Benjamin, Veatch, Andrea · 2025 · Journal of Clinical Oncology

Abstract

PURPOSE: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NSCLC). METHODS: Patients received Dato-DXd 6 mg/kg or docetaxel 75 mg/m 2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Objective response rate, duration of response, and safety were secondary end points. RESULTS: In total, 299 and 305 patients were randomly assigned to receive Dato-DXd or docetaxel, respectively. The median PFS was 4.4 months (95% CI, 4.2 to 5.6) with Dato-DXd and 3.7 months (95% CI, 2.9 to 4.2) with docetaxel (hazard ratio [HR], 0.75 [95% CI, 0.62 to 0.91]; P = .004). The median OS was 12.9 months (95% CI, 11.0 to 13.9) and 11.8 months (95% CI, 10.1 to 12.8), respectively (HR, 0.94 [95% CI, 0.78 to 1.14]; P = .530). In the prespecified nonsquamous histology subgroup, the median PFS was 5.5 versus 3.6 months (HR, 0.63 [95% CI, 0.51 to 0.79]) and the median OS was 14.6 versus 12.3 months (HR, 0.84 [95% CI, 0.68 to 1.05]). In the squamous histology subgroup, the median PFS was 2.8 versus 3.9 months (HR, 1.41 [95% CI, 0.95 to 2.08]) and the median OS was 7.6 versus 9.4 months (HR, 1.32 [95% CI, 0.91 to 1.92]). Grade ≥3 treatment-related adverse events occurred in 25.6% and 42.1% of patients, and any-grade adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8.8% and 4.1% of patients, in the Dato-DXd and docetaxel groups, respectively. CONCLUSION: Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.

Overview

CoChat Summary

TL;DR

In this randomized phase III trial of previously treated advanced/metastatic NSCLC, datopotamab deruxtecan (Dato-DXd) improved progression-free survival and response outcomes versus docetaxel, but did not significantly improve overall survival. Benefit was driven by patients with nonsquamous histology, while squamous histology showed no PFS advantage and possible inferiority.

Key findings

  • In the full analysis set, median PFS was 4.4 months with Dato-DXd vs 3.7 months with docetaxel (HR 0.75; 95% CI, 0.62 to 0.91; P = .004).
  • In patients with nonsquamous tumors, median PFS was 5.5 vs 3.6 months (HR 0.63; 95% CI, 0.51 to 0.79), and median OS was 14.6 vs 12.3 months (HR 0.84; 95% CI, 0.68 to 1.05).
  • In patients with squamous tumors, median PFS was 2.8 vs 3.9 months (HR 1.41; 95% CI, 0.95 to 2.08) and median OS was 7.6 vs 9.4 months (HR 1.32; 95% CI, 0.91 to 1.92).
  • Confirmed ORR was 26.4% with Dato-DXd vs 12.8% with docetaxel; median DOR was 7.1 vs 5.6 months.
  • Safety favored Dato-DXd for several high-grade outcomes: grade ≥3 TRAEs were 25.6% vs 42.1%, and treatment discontinuations were 8.1% vs 12.1%; however, adjudicated drug-related ILD occurred in 8.8% vs 4.1%, and 7 patients (2.4%) receiving Dato-DXd died from adjudicated drug-related ILD.

Methods

  • Randomized, open-label, global phase III trial (TROPION-Lung01) comparing Dato-DXd 6 mg/kg vs docetaxel 75 mg/m² IV every 3 weeks; crossover was not permitted.
  • Eligible patients had stage IIIB/C or IV NSCLC after prior therapy; the trial enrolled 299 patients to Dato-DXd and 305 to docetaxel.
  • Dual primary endpoints were PFS by blinded independent central review (RECIST 1.1) and OS; analyses used Kaplan-Meier estimates and stratified Cox regression, with safety assessed in treated patients.

Limitations

  • The paper states the open-label study design is a limitation.
  • The trial was not powered to demonstrate statistical significance within histologic subgroups; this is stated in the discussion and is evident from subgroup interpretation.
  • A slight imbalance in pretreatment dropout rates was observed (1% in Dato-DXd vs 5% in docetaxel), though the authors say it was unlikely to affect outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1200/jco-24-01544

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG 1. CONSORT diagram. Data cutoff: March 1, 2024. aOne patient in the docetaxel treatment group was randomly assigned twice; treatment was not initiated under the first patient identifier, and only the second patient identifier was included. A total of 305 unique patients were allocated to docetaxel. AE, adverse event; Dato-DXd, datopotamab deruxtecan; PD, progressive disease.
FIG 1. CONSORT diagram. Data cutoff: March 1, 2024. aOne patient in the docetaxel treatment group was randomly assigned twice; treatment was not initiated under the first patient identifier, and only the second patient identifier was included. A total of 305 unique patients were allocated to docetaxel. AE, adverse event; Dato-DXd, datopotamab deruxtecan; PD, progressive disease.CC BY-NC-ND · PubMed Central
FIG 2. PFS by treatment and key subgroups. Data cutoff: March 29, 2023. (A) Kaplan-Meier curves for PFS in the full analysis set, (B) HRs of PFS in key subgroups, (C) Kaplan-Meier curves for PFS in patients with nonsquamous histology, and (D) Kaplan-Meier curves for PFS in patients with squamous histology. PFS was assessed by blinded independent central review. Tick marks in the Kaplan-Meier curves represent censored data. HRs and CIs in the forest plot were calculated on the basis of the patient data in the electronic case report forms for the histology and actionable genomic alteration subgroups. aRegardless of histology. Dato-DXd, datopotamab deruxtecan; HR, hazard ratio; PFS, progression-free survival.
FIG 2. PFS by treatment and key subgroups. Data cutoff: March 29, 2023. (A) Kaplan-Meier curves for PFS in the full analysis set, (B) HRs of PFS in key subgroups, (C) Kaplan-Meier curves for PFS in patients with nonsquamous histology, and (D) Kaplan-Meier curves for PFS in patients with squamous histology. PFS was assessed by blinded independent central review. Tick marks in the Kaplan-Meier curves represent censored data. HRs and CIs in the forest plot were calculated on the basis of the patient data in the electronic case report forms for the histology and actionable genomic alteration subgroups. aRegardless of histology. Dato-DXd, datopotamab deruxtecan; HR, hazard ratio; PFS, progression-free survival.CC BY-NC-ND · PubMed Central
FIG 3. OS by treatment and key subgroups. Data cutoff: March 1, 2024. (A) Kaplan-Meier curves for OS in the full analysis set, (B) HRs of OS in key subgroups, (C) Kaplan-Meier curves for OS in patients with nonsquamous histology, and (D) Kaplan-Meier curves for OS in patients with squamous histology. Tick marks in the Kaplan-Meier curves represent censored data. HRs and CIs in the forest plot were calculated on the basis of the patient data in the electronic case report forms for the histology and actionable genomic alteration subgroups. aRegardless of histology. Dato-DXd, datopotamab deruxtecan; HR, hazard ratio; OS, overall survival.
FIG 3. OS by treatment and key subgroups. Data cutoff: March 1, 2024. (A) Kaplan-Meier curves for OS in the full analysis set, (B) HRs of OS in key subgroups, (C) Kaplan-Meier curves for OS in patients with nonsquamous histology, and (D) Kaplan-Meier curves for OS in patients with squamous histology. Tick marks in the Kaplan-Meier curves represent censored data. HRs and CIs in the forest plot were calculated on the basis of the patient data in the electronic case report forms for the histology and actionable genomic alteration subgroups. aRegardless of histology. Dato-DXd, datopotamab deruxtecan; HR, hazard ratio; OS, overall survival.CC BY-NC-ND · PubMed Central
FIG A1. Study design of TROPION-Lung01. Pretreated patients with advanced or metastatic NSCLC received Dato-DXd 6 mg/kg IV once every 3 weeks or docetaxel 75 mg/m2 IV once every 3 weeks. aFor patients with actionable genomic alterations, previously treated with one to two lines of approved alteration-targeted therapy, with platinum-based chemotherapy as the only previous line of cytotoxic therapy, with or without not more than one anti–PD-1/PD-L1 monoclonal antibody alone or in combination with a cytotoxic agent. For patients without actionable genomic alterations, previously treated with platinum-based chemotherapy and anti–PD-1/PD-L1 immunotherapy, either in combination as the only previous line of therapy or sequentially as the only two previous lines of therapy. For all patients, no previous docetaxel was permitted. bPatients with known KRAS mutations, in the absence of any driver genomic alterations, were eligible and had to meet previous therapy requirements for patients without actionable genomic alterations. cDay 1 of each 3-week cycle. dRadiographic disease progression, clinical progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of patient consent. ePer RECIST v1.1. fAssessed by BICR and investigator per RECIST v1.1. BICR, blinded independent central review; CR, complete response; Dato-DXd, datopotamab deruxtecan; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non–small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease; TTR, time to response.
FIG A1. Study design of TROPION-Lung01. Pretreated patients with advanced or metastatic NSCLC received Dato-DXd 6 mg/kg IV once every 3 weeks or docetaxel 75 mg/m2 IV once every 3 weeks. aFor patients with actionable genomic alterations, previously treated with one to two lines of approved alteration-targeted therapy, with platinum-based chemotherapy as the only previous line of cytotoxic therapy, with or without not more than one anti–PD-1/PD-L1 monoclonal antibody alone or in combination with a cytotoxic agent. For patients without actionable genomic alterations, previously treated with platinum-based chemotherapy and anti–PD-1/PD-L1 immunotherapy, either in combination as the only previous line of therapy or sequentially as the only two previous lines of therapy. For all patients, no previous docetaxel was permitted. bPatients with known KRAS mutations, in the absence of any driver genomic alterations, were eligible and had to meet previous therapy requirements for patients without actionable genomic alterations. cDay 1 of each 3-week cycle. dRadiographic disease progression, clinical progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of patient consent. ePer RECIST v1.1. fAssessed by BICR and investigator per RECIST v1.1. BICR, blinded independent central review; CR, complete response; Dato-DXd, datopotamab deruxtecan; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non–small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease; TTR, time to response.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 12 Not checked · 56 Own results and interpretations

30 more claims

Create a free account to see all 69 claims and to verify the 21 references still open.

See all claims — free account
  • It may state two separate claims as one. 20
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Leighl N, Paz-Ares L, Rodriguez Abreu D, et al: 65O Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. IOTECH 20:100535, 2023

Cited by

See all 244

Metadata

Authors
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Hong, M. H., Felip, E., Hall, R., Juan-Vidal, O., Brungs, D., Lu, S., Garassino, M., Chargualaf, M., Zhang, Y., Howarth, P., Uema, D., Lisberg, A., Sands, J., for the TROPION-Lung01 Trial Investigators, Martinengo, G. L., Puig, J., Brungs, D., Gao, B., Nagria, A., Karapetis, C., Parakh, S., Park, J., Catala, G., Forget, F., Ocak, S., Basappa, N., Liu, G., Menjak, I., Shieh, B., Lu, S., Luo, F., Sun, H., Wang, J., Yao, Y., Zemanova, M., Bennouna, J., Girard, N., Greillier, L., Lamour, C., Lena, H., Mascaux, C., Mazieres, J., Moro-Sibilot, D., Pérol, M., Pons-Tostivint, E., Westeel, V., Atmaca, A., Greil, C., Reinmuth, N., Schumann, C., Wehler, T., Wolf, J., Ho, J., Bocskei, C., Cappuzzo, F., de Marinis, F., Proto, C., Mencoboni, M., Novello, S., Salvagni, S., Parra, H. S., Daga, H., Goto, Y., Hayashi, H., Kitazono, S., Yoh, K., Ko, R., Kondo, M., Kozuki, T., Kurata, T., Mizutani, H., Ohashi, K., Oizumi, S., Okamoto, I., Sakaguchi, S., Ozasa, H., Sugawara, S., Tambo, Y., Tamiya, M., Tanaka, H., Okamoto, I., Lopez-Lopez, F., Ramirez Godinez, F. J., Rodriguez Cid, J. R., Cornelissen, R., Gans, S., Stigt, J., Kowalski, D., Lowczak, A., Milanowski, J., Mróz, R., Ramlau, R., Acosta-Rivera, M., Ahn, M.-J., Chae, Y. S., Hong, M. H., Kang, J.-H., Kim, S.-W., Kim, J.-S., Kim, S. H., Lee, K. H., Lee, Y. G., Shim, B. Y., Ledin, E., Poddubskaya, E., Daniel Chan, B. Y., Jain, A., Tan, C. S., Areses, M. C., Cobo, M., Domine, M., Felip, E., Pradera, J. F., Isla, D., Vidal, O. J., Majem, M., Paz-Ares, L., Provencio, M., Reguart, N., Baz, D. V., Cerciello, F., Früh, M., Chang, W.-C., Chang, G.-C., Huang, W.-T., Ling, C.-C., Wei, Y.-F., Yang, T.-Y., Ahmad, T., Gomes, F., Mansy, T., Bruno, D., Castine, M., Fang, B., Garassino, M., Hall, R., Halmos, B., Jahangir, K., Johnson, M., Johnson, T., Kalmadi, S., Lawler, W., Lisberg, A., Sadiq, A., Sands, J., Solomon, B., & Veatch, A.
Affiliations
  • Kyushu University Hospital (JP)
  • Hospital Universitario Virgen Macarena, Seville, Spain
  • Hospital Universitari i Politecnic La Fe, Valencia, Spain
  • Daiichi Sankyo (United States) (US)
Venue
Journal of Clinical Oncology
Published
2025-01-20
Volume
43
Issue
3
Pages
260-272
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4402350756
Cited by
244
References
32
Citations by year
2026: 138 · 2025: 97
FWCI
70.88
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
  • Open Access CRIS of the University of Bern
Funders
Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
datopotamab deruxtecan, docetaxel, non-small cell lung cancer, metastatic lung cancer, previously treated patients, progression-free survival, overall survival, antibody-drug conjugates, lung squamous cell carcinoma, treatment safety, objective response rate, duration of response
MeSH terms
Docetaxel, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. https://app.cochat.ai/papers/10.1200/jco-24-01544
The paper
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Hong, M. H., Felip, E., Hall, R., Juan-Vidal, O., Brungs, D., . . . Veatch, A. (2025). Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.